This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harukuni, I. Articles by Faraci, F. M. Search for Related Content PubMed PubMed Citation Articles by Harukuni, I. Articles by Faraci, F. M. Related Collections Brain Circulation and Metabolism Emergency treatment of Stroke Neuroprotectors Other Stroke Treatment - Medical

(Stroke. 2000;31:976.)
© 2000 American Heart Association, Inc.

Original Contributions

₁-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion

Izumi Harukuni, MD; Anish Bhardwaj, MD; Amanda B. Shaivitz, BA; A. Courtney DeVries, PhD; Edythe D. London, PhD; Patricia D. Hurn, PhD; Richard J. Traystman, PhD Jeffrey R. Kirsch, MD

From the Departments of Anesthesiology/Critical Care Medicine (I.H., A.B., A.B.S., A.C.D., P.D.H., R.J.T., J.R.K.) and Neurology (A.B., J.R.K.), Johns Hopkins University School of Medicine, Baltimore, Md, and National Institute on Drug Abuse (E.D.L.), Baltimore, Md.

Correspondence to Jeffrey R. Kirsch, MD, Blalock 1412, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287-4963. E-mail jkirsch{at}jhmi.edu

Background and Purpose—We previously showed that the intravenous administration of the potent ₁-receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP) provides neuroprotection against transient focal cerebral ischemia and that the protection depends on treatment duration. We tested the hypothesis that PPBP would provide neuroprotection in a model of transient focal ischemia and 7 days of reperfusion in the rat as assessed with neurobehavioral outcome and infarction volume.

Methods—Under the controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO) with the intraluminal suture occlusion technique. We used laser Doppler flowmetry to assess MCAO. At 60 minutes after the onset of ischemia, rats were randomly assigned to 1 of 4 treatment groups in a blinded fashion and received a continuous intravenous infusion of control saline or 0.1, 1, or 10 µmol · kg^-1 · h^-1 PPBP for 24 hours. Neurobehavioral evaluation was performed at baseline (3 to 4 days before MCAO) and at 3 and 7 days of reperfusion. Infarction volume was assessed with triphenyltetrazolium chloride staining on day 7 of reperfusion in all rats.

Results—Triphenyltetrazolium chloride–determined infarction volume of ipsilateral cortex was smaller in rats treated with 10 µmol · kg^-1 · h^-1 PPBP (n=15, 68±12 mm³, 18±3% of contralateral structure, P<0.05) (mean±SEM) compared with corresponding rats treated with saline (n=15, 114±11 mm³, 31±3% of contralateral structure). PPBP did not provide significant neuroprotection in the caudoputamen complex. Although MCAO was associated with several alterations in behavior, the treatment with PPBP had no effect on behavioral outcomes.

Conclusions—The data demonstrate that the potent ₁-receptor ligand PPBP decreases cortical infarction volume without altering neurobehavior after transient focal ischemia and prolonged reperfusion in the rat.

Editorial Comment

Frank M. Faraci, PhD, Guest Editor

Department of Internal Medicine, Cardiovascular Division, University of Iowa College of Medicine, Iowa City, Iowa

This article has been cited by other articles:

				S. Yang, A. Bhardwaj, J. Cheng, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Sigma Receptor Agonists Provide Neuroprotection In Vitro by Preserving bcl-2 Anesth. Analg., May 1, 2007; 104(5): 1179 - 1184. [Abstract] [Full Text] [PDF]

				J. Meunier, J. Ieni, and T. Maurice Antiamnesic and Neuroprotective Effects of Donepezil against Learning Impairments Induced in Mice by Exposure to Carbon Monoxide Gas J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1307 - 1319. [Abstract] [Full Text] [PDF]

				T. Goyagi, A. Bhardwaj, R. C. Koehler, R. J. Traystman, P. D. Hurn, and J. R. Kirsch Potent {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats Anesth. Analg., February 1, 2003; 96(2): 532 - 538. [Abstract] [Full Text] [PDF]

				T. Goyagi, S. Goto, A. Bhardwaj, V. L. Dawson, P. D. Hurn, and J. R. Kirsch Neuroprotective Effect of {{sigma}}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production Stroke, July 1, 2001; 32(7): 1613 - 1620. [Abstract] [Full Text] [PDF]

				R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes Stroke, March 1, 2001; 32(3): 783 - 787. [Abstract] [Full Text] [PDF]